

PRESS RELEASE VIII - 02/2022

## Final Conference and successful conclusion of the PANBioRA project

*After four successful years of project implementation, PANBioRA has now come to an end. The final conference in December 2021 summarised the project's objectives, valuable results and achievements and gave an outlook on the time ahead.*


On 31<sup>st</sup> December 2021, the EU-funded project PANBioRA – “Personalised and generalised integrated biomaterial risk assessment” – has come to a successful conclusion after four years. Against the background of insufficient risk assessment in the field of biomaterial applications in the healthcare system, the project's main objective was to provide a more intelligent way of evaluating and selecting the most suitable biomaterial for potential patient-specific implants. To achieve this goal, 17 project partners from 11 different European countries successfully worked together.



The PANBioRA prototype: cytotoxicity test loading

The outcome of this fruitful research and collaboration has been presented at the project's final conference on 1<sup>st</sup> December 2021 in Strasbourg, France. Due to current COVID-19 restrictions the conference took place in a hybrid format, uniting on-site and online participants in the best possible way. After a general project overview by the project coordinator, two main project results, the PANBioRA prototype as well as the [Risk Radar and Risk Rating tool](#), have been presented. For demonstration, an automated cytotoxicity test with electrochemical sensors and real-time imaging was selected. For the Risk Radar the use case of breast implants and COVID-19 was demonstrated. Furthermore, for the

Risk Rating tool the data generated for 8 established biomaterials with PANBioRA protocols was shown.



The screenshot shows a presentation slide titled "Outputs" with the PANBioRA logo in the top left. The slide lists the following results:

- » Results:
  - Radar map
  - Network graph
  - Trend monitoring
  - Auto-generated reports (in PDF) with source identification
- » Automatic update of results based on user preference
- » Guidance: Online Help & Information (on Tool)

The slide also features a radar map, a network graph, and a line graph. A video call interface is visible on the right side of the slide, showing a participant and several icons for other participants (AF, TZ, AV, GM, +29).

Presentation of the PANBioRA Risk Radar and Risk Rating tool



These were followed by an overview on relevant standards and regulations in the PANBioRA framework, as well as first-hand experiences and impacts from a clinical point of view. An outlook on future activities in the scope of PANBioRA after the official end of the project concluded the final conference. During the ensuing Steering Committee Meeting all partners pronounced their will to continue the collaboration in the future, as for example in new projects or within a PANBioRA spin-off.

Over the past four years, PANBioRA has been an extraordinarily exciting journey that brought many new insights, connections and ideas thanks to a remarkable collaboration and engagement of all project partners. We encourage all our interested stakeholders and followers to stay in touch via our social media accounts and to visit our [website](#) and [showroom](#) to take a look at last published project news, articles and publications as well as the prototype.

---

For further information please visit [www.panbiora.eu](http://www.panbiora.eu) or follow PANBioRA on [Facebook](#), [LinkedIn](#), [Twitter](#), [Research Gate](#) and check out our project video: [YouTube](#).

**Project coordinator:**

**Scientific coordinator:**

Dr. Nihal Engin Vrana | [evrana@sparthamedical.eu](mailto:evrana@sparthamedical.eu) |

**Administrative coordinator:**

Steinbeis 2i GmbH

Timo Doll | [doll@steinbeis-europa.de](mailto:doll@steinbeis-europa.de) | +49 721 93519141

PANBioRA is coordinated by Steinbeis 2i GmbH in cooperation with 16 partners: Spartha Medical (Scientific Coordinator), Dolmen Design and Innovation Limited, Biodevice Systems, Protobios, Elvsys SAS, Steinbeis Advanced Risk Technologies Institute doo Kragujevac, Steinbeis Advanced Risk Technologies GmbH, Commissariat A L'Energie Atomique Et Aux Energies Alternatives, Pro-active, Aalto-Korkeakoulusäätiö, Turgut Ozal Education SHA, The University of Nottingham, Agencia Estatal Consejo Superior de Investigaciones Científicas, Dublin City University, Institut National de la Santé et de la Recherche Medicale, Centre Hospitalier Universitaire de Liège

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 760921.

